Methylation

Agilent at AACR 2024: Empowering Breakthroughs in Cancer Research and Diagnostics

Retrieved on: 
Wednesday, April 3, 2024
Oncology, Health, Health Technology, Genetics, Other Science, Research, Science, Genomics, IHC, Methylation, Partnership, Laser, TMB, NGS, MSI, DNA, Biomarker, Cancer, Hydrofluoroolefin, Biology, Medicine, Imperial College London, AACR, Microsatellite instability, Neoplasm, Therapy, Agilent Technologies, Liquid biopsy, Machine learning, RNA-Seq, University of Oxford, CMO, Medical imaging

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences and diagnostics, announced today its participation in the American Association for Cancer Research Annual Meeting (AACR) .

Key Points: 
  • Agilent Technologies Inc. (NYSE: A), a global leader in life sciences and diagnostics, announced today its participation in the American Association for Cancer Research Annual Meeting (AACR) .
  • Agilent Avida - Agilent Avida’s new cutting-edge target enrichment solutions enable simultaneous DNA and methylation profiling from a single sample.
  • Agilent SureSelect Cancer Custom panels - Agilent SureSelect Cancer Custom panels offer the ability to add new and emerging biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI), to custom tumor genomic profiling assays.
  • AACR attendees can also explore multiple Agilent research posters and over 50 additional customer posters highlighting Agilent instruments and solutions.

GRAIL Presents New Data on Galleri® and Its Methylation Platform at the Annual American Association for Cancer Research (AACR) Meeting

Retrieved on: 
Wednesday, March 27, 2024
Biotechnology, Other Health, Health, General Health, Oncology, Health Technology, Medical Devices, Research, Genetics, Science, Clinical Trials, Prostate cancer, Survival, Nucleic acid thermodynamics, Methylation, Cancer, MD, Medicine, AACR, Gene expression, Molecular biology, Medical imaging

“The data we are presenting at AACR continue to support the potential of GRAIL’s Methylation Platform to transform cancer care and the potential benefits of population-scale asymptomatic (or early) cancer detection,” said Jeffrey Venstrom, MD, Chief Medical Officer at GRAIL.

Key Points: 
  • “The data we are presenting at AACR continue to support the potential of GRAIL’s Methylation Platform to transform cancer care and the potential benefits of population-scale asymptomatic (or early) cancer detection,” said Jeffrey Venstrom, MD, Chief Medical Officer at GRAIL.
  • Exhibiting 4-year overall survival follow-up demonstrating the prognostic significance of detecting cancer with a methylation-based cfDNA platform like Galleri.
  • Illustrating data demonstrating the power of Galleri to preferentially detect high grade, clinically significant prostate cancer over indolent cases.
  • In the precision oncology setting, GRAIL will discuss the adaptability of its Methylation Platform in identifying cancer histological and molecular subtypes through blood samples.

GRAIL Announces Novel Risk Classification Test to Be Used in Lung Cancer Study

Retrieved on: 
Monday, March 18, 2024
Software, Biotechnology, Internet, Oncology, Health, Data Management, Technology, Clinical Trials, MD, CDX, Cancer, Methylation, Recurrence, Classification, Clinical trial, AstraZeneca, Medical imaging

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today that participants from Japan, via a collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN), will have their samples tested using GRAIL’s novel risk classification test on its Methylation Platform.

Key Points: 
  • GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today that participants from Japan, via a collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN), will have their samples tested using GRAIL’s novel risk classification test on its Methylation Platform.
  • This assay has been validated for recurrence risk classification in newly diagnosed Stage I lung adenocarcinoma.
  • GRAIL’s Methylation Platform enables tissue-free, blood-based cancer detection that can be customized for a suite of precision applications across hematological and solid tumors, including risk stratification, molecular subtyping, and molecular response.
  • In December 2023, GRAIL announced the analytical and clinical validation of a novel prognostic test in Stage I lung adenocarcinoma.

PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions

Retrieved on: 
Tuesday, March 12, 2024
Gene, Methylation, FTD, FMR1, ALS, Associate, Myotonic dystrophy, Abraxis BioScience, Huntington's disease, DNA, Apple IIe, Ataxia, Laboratory, University College London, Frontotemporal dementia, DSM-IV codes, Mosaic, High fidelity, Instability

MENLO PARK, Calif., March 12, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the PureTarget repeat expansion panel, a new solution designed to enable the comprehensive analysis of 20 genes associated with serious neurological disorders, including challenging-to-sequence genes with tandem repeat expansions. The new long-read workflow can minimize iterative analysis using legacy technology, and reduce the time needed to identify disease-causing variants and associated methylation signatures.

Key Points: 
  • "This product uses a differentiated method to do targeted long-read sequencing of DNA in its pure state.
  • Continuing the commitment to deliver comprehensive solutions, PacBio has prioritized delivering end-to-end workflows with their latest products.
  • The PureTarget Repeat Expansion Panel workflow utilizes the recently announced Nanobind PanDNA kit , ensuring robust results optimized for Revio and Sequel IIe users.
  • Customers can multiplex up to 48 samples on the PacBio Revio sequencing system and 24 samples on the PacBio Sequel IIe sequencing system.

Wistar Scientists Discover Link Between Leaky Gut and Accelerated Biological Aging

Retrieved on: 
Friday, February 23, 2024
Methylation, Dysbiosis, Culture, Penn Center, Health, Bacteria, University, Subtypes of HIV, Life Length, Wistar Institute, Bangladesh Technical Education Board, Ileum, Infection, NIH, AIDS, Glass, Metabolomics, Nucleotide, DSM-IV codes, Biomedical Research, HIV/AIDS research, Wistar, University of Pittsburgh, DNA, Immune system, National Institutes of Health, Leiden University Medical Center, Weill Cornell Medicine, Hannum, Research, Inflammation, Blood, Ageing, Cancer, Cell biology, Microbiome, Rush University, HIV, DNA methylation, Vaccine

Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.

Key Points: 
  • Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.
  • A prime suspect in this aging puzzle is the gut microbiome and its potential leakage into the bloodstream.
  • The Abdel-Mohsen lab investigates how gut leakage can impact the immune system and lead to chronic inflammation, which may accelerate aging.
  • Their analysis revealed a significant connection between disrupted gut microbiomes, increased intestinal permeability (leaky gut), and faster biological aging.

Fujirebio Europe Expands Its Portfolio With Introduction of the Innovative PreCursor-M AnoGYN assay (RUO) for Methylation Testing in Anal Specimens

Retrieved on: 
Tuesday, March 5, 2024
Oncology, Medical Supplies, Health, Medical Devices, Research, Science, Biotechnology, Methylation, Cervical cancer, Woman, ASCL1, Dysplasia, Triage, Partnership, Multiple endocrine neoplasia, Test management, Human papillomavirus infection, Fujirebio, Risk, SCC, Biomarker, RUO, Incidence, Patient, Carcinoma, Carcinogenesis, Gene, HPV, HSIL, Host, Anal cancer, Lithium, DNA methylation, DNA, IVD, Cancer, CIN, Vaccine

Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.

Key Points: 
  • Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.
  • In analogy with cervical cancer screening, the screening and treatment of HSIL to prevent anal cancer in high-risk groups are under debate.
  • Host cell deoxyribonucleic acid methylation markers for the detection of high-grade anal intraepithelial neoplasia and anal cancer.
  • Analytical validation and diagnostic performance of the ASCL1/ZNF582 methylation test for detection of high-grade anal intraepithelial neoplasia and anal cancer.

Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 4, 2024
Pharmaceutical, Health, Oncology, Clinical Trials, DNA, Methylation, Viral, Orphan drug, GSK, AMG, FDA, Amgen, Indication, Marketing, Proteolysis, Docetaxel, Cell, Proteolysis targeting chimera, Glioblastoma, Therapy, Cancer, TDP1, Half-life, Survival, PRMT5, Acute myeloid leukemia, Research, Pharmaceutical industry

The "Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024" report has been added to ResearchAndMarkets.com's offering.
  • Beyond monotherapies, combination strategies are also being explored in preclinical and clinical trials to enhance PRMT5 inhibition efficacy.
  • However, realizing the full clinical and commercial potential will require validating efficacy and defining suitable patient populations through biomarker-guided trials.
  • Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024 Report Highlights:
    PRMT5 Targeted Therapies Clinical Trials by Company, Indication & Phase
    PRMT5 Targeted Therapies in Clinical Trials: >25
    PRMT5 Targeted Therapies Research & Market Trends by Region: US, UK, EU, China & Canada

Hybribio Calls for Raising International HPV Awareness

Retrieved on: 
Monday, March 4, 2024
International, Hospital, Cervical cancer, Woman, IPVS, SOX1, Methylation, Cancer, Human papillomavirus infection, Wart, Vaccination, World Health Organization, Fluorescence, Organization, HPV, Vagina, WHO, PCR, NMPA

On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.

Key Points: 
  • On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.
  • In this case, raising HPV awareness, getting timely vaccination and high-quality screening together contribute significantly to the prevention of HPV infection and related diseases.
  • Hybribio has developed a complete HPV molecular diagnostic solution covering 14 High-risk HPV GenoArray Diagnostic Kit, 14 High-risk HPV with 16/18 Genotyping Real-time PCR Kit, 14 High-risk HPV E6/E7 mRNA Real-time PCR Kit (PCR with Fluorescent Probe), 21 HPV GenoArray Diagnostic Kit, 37 HPV GenoArray Diagnostic Kit, 13 High-risk HPV Real-time PCR Kit, 23 HPV Genotyping Real-time PCR Kit, SOX1 and PAX1 Methylation Real-time PCR Kit.
  • Raising international HPV awareness is the very first step against cervical cancer.

Hybribio Calls for Raising International HPV Awareness

Retrieved on: 
Monday, March 4, 2024
International, Hospital, Cervical cancer, Woman, IPVS, SOX1, Methylation, Cancer, Human papillomavirus infection, Wart, Vaccination, World Health Organization, Fluorescence, Organization, HPV, Vagina, WHO, PCR, NMPA

On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.

Key Points: 
  • On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.
  • In this case, raising HPV awareness, getting timely vaccination and high-quality screening together contribute significantly to the prevention of HPV infection and related diseases.
  • Hybribio has developed a complete HPV molecular diagnostic solution covering 14 High-risk HPV GenoArray Diagnostic Kit, 14 High-risk HPV with 16/18 Genotyping Real-time PCR Kit, 14 High-risk HPV E6/E7 mRNA Real-time PCR Kit (PCR with Fluorescent Probe), 21 HPV GenoArray Diagnostic Kit, 37 HPV GenoArray Diagnostic Kit, 13 High-risk HPV Real-time PCR Kit, 23 HPV Genotyping Real-time PCR Kit, SOX1 and PAX1 Methylation Real-time PCR Kit.
  • Raising international HPV awareness is the very first step against cervical cancer.

Wasatch Biolabs Launches Proprietary Targeted DNA Methylation Sequencing Service for Researchers and Healthcare Providers

Retrieved on: 
Tuesday, February 13, 2024
Methylation, Nanopore, A-DNA, Oxford Nanopore Technologies, WBL, Cancer, Drug development, Entrepreneurship, RNA, Gene expression, Nanopore sequencing, Disease, PCR, DNA methylation, Research, DNA, AMR, Fine chemical

HEBER CITY, Utah, Feb. 13, 2024 /PRNewswire/ -- Wasatch Biolabs (WBL) , a subsidiary of Renew Biotechnologies and a certified Oxford Nanopore Technologies' laboratory, launches a proprietary Targeted DNA Methylation Sequencing Service for researchers and clinical service providers.

Key Points: 
  • HEBER CITY, Utah, Feb. 13, 2024 /PRNewswire/ -- Wasatch Biolabs (WBL) , a subsidiary of Renew Biotechnologies and a certified Oxford Nanopore Technologies' laboratory, launches a proprietary Targeted DNA Methylation Sequencing Service for researchers and clinical service providers.
  • The DNA methylation service is being released among WBL's first wave of Oxford Nanopore-based sequencing services, and is the company's first big step toward making Oxford Nanopore sequencing and the power of epigenetics more accessible to researchers and healthcare providers.
  • Bisulfite sequencing, which involves chemical treatment of DNA with sodium bisulfite and PCR amplification, remains the de facto standard for DNA methylation analysis.
  • In addition to its proprietary DNA methylation sequencing service, WBL also offers other Oxford Nanopore assay-based sequencing services, including whole genome, cDNA, and RNA sequencing, among others, to researchers and clinical service providers.